Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Similar articles for PubMed (Select 21056012)

1.

Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.

Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR.

Cancer Cell. 2010 Nov 16;18(5):499-509. doi: 10.1016/j.ccr.2010.10.015. Epub 2010 Nov 4.

2.

Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice.

Rowley M, Ohashi A, Mondal G, Mills L, Yang L, Zhang L, Sundsbak R, Shapiro V, Muders MH, Smyrk T, Couch FJ.

Gastroenterology. 2011 Apr;140(4):1303-1313.e1-3. doi: 10.1053/j.gastro.2010.12.039. Epub 2011 Jan 1.

3.

Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.

Feldmann G, Karikari C, dal Molin M, Duringer S, Volkmann P, Bartsch DK, Bisht S, Koorstra JB, Brossart P, Maitra A, Fendrich V.

Cancer Biol Ther. 2011 Jun 1;11(11):959-68. Epub 2011 Jun 1.

4.

Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.

Hermann PC, Sancho P, Cañamero M, Martinelli P, Madriles F, Michl P, Gress T, de Pascual R, Gandia L, Guerra C, Barbacid M, Wagner M, Vieira CR, Aicher A, Real FX, Sainz B Jr, Heeschen C.

Gastroenterology. 2014 Nov;147(5):1119-33.e4. doi: 10.1053/j.gastro.2014.08.002. Epub 2014 Aug 12.

PMID:
25127677
5.

Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.

Qiu W, Sahin F, Iacobuzio-Donahue CA, Garcia-Carracedo D, Wang WM, Kuo CY, Chen D, Arking DE, Lowy AM, Hruban RH, Remotti HE, Su GH.

Oncotarget. 2011 Nov;2(11):862-73.

6.

A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.

Yamaguchi T, Ikehara S, Nakanishi H, Ikehara Y.

J Pathol. 2014 Oct;234(2):228-38. doi: 10.1002/path.4402. Epub 2014 Aug 4.

PMID:
25042889
7.

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong TD, Jaffee EM.

Gastroenterology. 2014 Jun;146(7):1784-94.e6. doi: 10.1053/j.gastro.2014.02.055. Epub 2014 Mar 6.

8.

Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor.

Hattori H, Skoulidis F, Russell P, Venkitaraman AR.

Mol Cancer Ther. 2011 Apr;10(4):670-8. doi: 10.1158/1535-7163.MCT-10-0781. Epub 2011 Feb 2.

9.
10.

Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, Kern SE.

Cancer Res. 1996 Dec 1;56(23):5360-4.

11.

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.

Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Evans TR, Sansom OJ.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):246-51. doi: 10.1073/pnas.0908428107. Epub 2009 Dec 14.

12.

N-cadherin haploinsufficiency increases survival in a mouse model of pancreatic cancer.

Su Y, Li J, Witkiewicz AK, Brennan D, Neill T, Talarico J, Radice GL.

Oncogene. 2012 Oct 11;31(41):4484-9. doi: 10.1038/onc.2011.574. Epub 2011 Dec 12.

13.

BRCA2 and TP53 collaborate in tumorigenesis in zebrafish.

Shive HR, West RR, Embree LJ, Golden CD, Hickstein DD.

PLoS One. 2014 Jan 29;9(1):e87177. doi: 10.1371/journal.pone.0087177. eCollection 2014.

14.

Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions.

Carrière C, Gore AJ, Norris AM, Gunn JR, Young AL, Longnecker DS, Korc M.

Gastroenterology. 2011 Sep;141(3):1091-101. doi: 10.1053/j.gastro.2011.05.041. Epub 2011 May 27.

15.

Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.

Shi G, DiRenzo D, Qu C, Barney D, Miley D, Konieczny SF.

Oncogene. 2013 Apr 11;32(15):1950-8. doi: 10.1038/onc.2012.210. Epub 2012 Jun 4.

16.

Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis.

Cano CE, Hamidi T, Garcia MN, Grasso D, Loncle C, Garcia S, Calvo E, Lomberk G, Dusetti N, Bartholin L, Urrutia R, Iovanna JL.

Gut. 2014 Jun;63(6):984-95. doi: 10.1136/gutjnl-2013-305221. Epub 2013 Sep 11.

PMID:
24026351
17.

Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model.

Ray KC, Bell KM, Yan J, Gu G, Chung CH, Washington MK, Means AL.

PLoS One. 2011 Feb 2;6(2):e16786. doi: 10.1371/journal.pone.0016786.

18.

BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.

Ottini L, Masala G, D'Amico C, Mancini B, Saieva C, Aceto G, Gestri D, Vezzosi V, Falchetti M, De Marco M, Paglierani M, Cama A, Bianchi S, Mariani-Costantini R, Palli D.

Cancer Res. 2003 Jan 15;63(2):342-7.

19.

BRCA2 dysfunction promotes malignant transformation of pancreatic intraepithelial neoplasia.

Wang Q, Liu H, Liu T, Shu S, Jiang H, Cheng S, Yuan Y, Yang W, Wang L.

Anticancer Agents Med Chem. 2013 Feb;13(2):261-9.

PMID:
22934697
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk